J.J. McCarthy's redshirt rookie season in the NFL hasn't gone to plan. In his return from last year's torn meniscus, the Vikings signal-caller has started just six of a possible 12 games, struggling ...

Jackson Country Central (JCC) High School star Roman Voss officially added 2025 Minnesota Mr. Football to his trophy case on Sunday. A huge congrats to Roman on being ...

T.J. Holmes and Amy Robach confirmed their engagement earlier in October 2025, but don't expect too many further updates from the pair. "We are not trying to make announcements," T.J. tells HELLO!, ...

Jessie J knows something about what Princess Kate has been through. The British singer, during an appearance on the U.K. program "The Morning," said she was "briefed not to" hug the princess during ...

Joseph Schwartz, the disgraced nursing home mogul charged in a multi-million-dollar tax fraud involving his troubled New Jersey-based empire, has been granted a full pardon by President Trump after ...

For the past several years, America has been using its young people as lab rats in a sweeping, if not exactly thought-out, education experiment. Schools across the country have been lowering standards ...

Math scores in the US have been so bad for so long that teachers could be forgiven for trying anything to improve them. Unfortunately, many of the strategies they’re using could be making things worse ...

O.J. Simpson’s estate has accepted a $58 million claim from the father of Ron Goldman, decades after a jury said the football and movie star was liable for the man’s fatal stabbing. But it doesn’t ...

Nov 6 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's (JNJ.N), opens new tab drug Caplyta as an add-on treatment for adults with major depressive ...

(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta as an add-on therapy with antidepressants for the treatment of major ...

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...